Kengo Takeuchi

21.3k total citations · 4 hit papers
339 papers, 12.0k citations indexed

About

Kengo Takeuchi is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kengo Takeuchi has authored 339 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pathology and Forensic Medicine, 146 papers in Oncology and 104 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kengo Takeuchi's work include Lymphoma Diagnosis and Treatment (121 papers), Lung Cancer Treatments and Mutations (61 papers) and Viral-associated cancers and disorders (40 papers). Kengo Takeuchi is often cited by papers focused on Lymphoma Diagnosis and Treatment (121 papers), Lung Cancer Treatments and Mutations (61 papers) and Viral-associated cancers and disorders (40 papers). Kengo Takeuchi collaborates with scholars based in Japan, United States and India. Kengo Takeuchi's co-authors include Hiroyuki Mano, Manabu Soda, Yuichi Ishikawa, Young Lim Choi, Yuki Togashi, Satoko Hatano, Sakae Okumura, Yoshihiro Yamashita, Ken Nakagawa and Seiji Sakata and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Physical Review Letters.

In The Last Decade

Kengo Takeuchi

316 papers receiving 11.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RET, ROS1 and ALK fusions in lung cancer

2012 963 citations Kengo Takeuchi, Manabu Soda et al. profile →
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

2010 915 citations Young Lim Choi, Manabu Soda et al. profile →
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

2009 557 citations Kengo Takeuchi, Young Lim Choi et al. Clinical Cancer Research profile →
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

2013 449 citations Katsuyuki Kiura, Makoto Nishio et al. profile →

Peers

Countries citing papers authored by Kengo Takeuchi

Since Specialization

Citations

This map shows the geographic impact of Kengo Takeuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kengo Takeuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kengo Takeuchi more than expected).

Fields of papers citing papers by Kengo Takeuchi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kengo Takeuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kengo Takeuchi. The network helps show where Kengo Takeuchi may publish in the future.

Co-authorship network of co-authors of Kengo Takeuchi

This figure shows the co-authorship network connecting the top 25 collaborators of Kengo Takeuchi. A scholar is included among the top collaborators of Kengo Takeuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kengo Takeuchi. Kengo Takeuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The association between CD34 expression status and the clinicopathological behavior of dedifferentiated liposarcoma 2024 ·Pathology - Research and Practice ·(unknown), Rikuo Machinami, Seiichi Matsumoto, Keisuke Ae, Yu Takahashi, Nobuyuki Hiruta, Kengo Takeuchi	0
2	Availability of genome-matched therapy based on clinical practice 2024 ·International Journal of Clinical Oncology ·Naomi Hayashi, Seiichi Mori, Akihiro Ohmoto, Ippei Fukada, (unknown), Mari Hosonaga, Xiaofei Wang, Arisa Ueki, Kazuma Kiyotani, Akiko Tonooka, Kengo Takeuchi, Shunji Takahashi	3
3	MHC class I loss is associated with biliary/progenitor cell features and “cold” tumor-immune microenvironment in hepatocellular carcinoma 2023 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Yasuyuki Shigematsu, (unknown), (unknown), (unknown), Hiroaki Kanda, Yu Takahashi, Yutaka Takazawa, Kengo Takeuchi, Kentaro Inamura	5
4	Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm 2023 ·Modern Pathology ·Kana Sakamoto, Satoko Baba, (unknown), Shuji Momose, (unknown), Akiko Tonooka, Ryo Ichinohasama, Emi Takakuwa, Hideki Nakasone, Koichi Ohshima, Kengo Takeuchi	2
5	Combined Merkel Cell Carcinoma with Nodal Presentation: Report of a Case Diagnosed with Excisional but Not Incisional Biopsy and Literature Review 2023 ·Diagnostics ·Chih‐Yi Liu, (unknown), Kengo Takeuchi, Shih‐Sung Chuang	6
6	Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer 2022 ·Cancer Science ·(unknown), Noriko Yanagitani, Sumie Koike, Siew‐Kee Low, Satoshi Takagi, Satoko Baba, Kengo Takeuchi, Makoto Nishio, Naoya Fujita, Ryohei Katayama	8
7	Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients 2020 ·Blood Advances ·Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, Lorenzo Cerroni, Caterina Giovanna Valentini, Tomohiro Aoki, Ritsuro Suzuki, Kengo Takeuchi, Arthur E. Frankel, Carlo Cota, David Ghez, Ronan Le Calloch, Livio Pagano, Tony Petrella	41
8	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma 2019 ·BMC Cancer ·Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, Ho Sup Lee, Sung Yong Oh, Ho‐Jin Shin, Jee Hyun Kong, Jun Ho Yi, Kana Sakamoto, Young Hyeh Ko, Jooryung Huh, Seung‐Sook Lee, Kengo Takeuchi, Dong‐Yeop Shin, Cheolwon Suh, Won Seog Kim	20
9	Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA 2019 ·Analytical Chemistry ·Yoshimi Haga, Motohide Uemura, Satoko Baba, Kentaro Inamura, Kengo Takeuchi, Norio Nonomura, Koji Ueda	48
10	Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib 2014 ·Clinical Cancer Research ·Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw	222
11	A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Manabu Soda, Kazutoshi Isobe, Akira Inoue, Makoto Maemondo, Satoshi Oizumi, Yuka Fujita, Akihiko Gemma, Yoshihiro Yamashita, Toshihide Ueno, Kengo Takeuchi, Young Lim Choi, Hitoshi Miyazawa, Tomoaki Tanaka, Koichi Hagiwara, Hiroyuki Mano, (unknown)	96
12	Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification 2011 ·Clinical Cancer Research ·Kengo Takeuchi, Manabu Soda, Yuki Togashi, Emiko Sugawara, Satoko Hatano, Reimi Asaka, Sakae Okumura, Ken Nakagawa, Hiroyuki Mano, Yuichi Ishikawa	77
13	Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial 2011 ·Journal of Clinical Oncology ·Takashi Watanabe, Kensei Tobinai, Taro Shibata, Kunihiro Tsukasaki, Yasuo Morishima, Nobuo Maseki, Tomohiro Kinoshita, Takayo Suzuki, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Masafumi Taniwaki, Naokuni Uike, Kengo Takeuchi, Shigeru Nawano, Takashi Terauchi, Tomomitsu Hotta	45
14	EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration 2010 ·Clinical Cancer Research ·Yuichi Sakairi, Takahiro Nakajima, Kazuhiro Yasufuku, Dai Ikebe, Hajime Kageyama, Manabu Soda, Kengo Takeuchi, Makiko Itami, Toshihiko Iizasa, Ichiro Yoshino, Hiroyuki Mano, Hideki Kimura	125
15	Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. 2010 ·PubMed ·Hisakazu Nishimori, Shunji Takahashi, Katsuyuki Kiura, Daisuke Ennishi, Takayuki Kobayashi, Koji Sano, Eiji Shinozaki, Masahiro Yokoyama, Yuko Mishima, Yasuhito Terui, Keisho Chìn, Nobuyuki Mizunuma, Yoshinori Ito, Seiichiro Nishimura, Kengo Takeuchi, Yuichi Ishikawa, Masahiko Oguchi, Mitsune Tanimoto, Kiyohiko Hatake	5
16	An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy 2009 ·Clinical Cancer Research ·Yuji Mishima, Natsuhiko Sugimura, (unknown), Yasuhito Terui, Kengo Takeuchi, (unknown), Daisuke Ennishi, Hiroaki Asai, Masahiro Yokoyama, Kiyotsugu Kojima, Kiyohiko Hatake	13
17	KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer breakdown → 2009 ·Clinical Cancer Research ·Kengo Takeuchi, Young Lim Choi, Yuki Togashi, Manabu Soda, Satoko Hatano, Kentaro Inamura, Shuji Takada, Toshihide Ueno, Yoshihiro Yamashita, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Yuichi Ishikawa, Hiroyuki Mano	557
18	Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer 2008 ·Cancer Research ·Young Lim Choi, Kengo Takeuchi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Toru Hamada, Hidenori Haruta, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Toshihide Ueno, Shuji Takada, Yoshihiro Yamashita, Yukihiko Sugiyama, Yuichi Ishikawa, Hiroyuki Mano	346
19	A mouse model for EML4-ALK -positive lung cancer 2008 ·Proceedings of the National Academy of Sciences ·Manabu Soda, Shuji Takada, Kengo Takeuchi, Young Lim Choi, Munehiro Enomoto, Toshihide Ueno, Hidenori Haruta, Toru Hamada, Yoshihiro Yamashita, Yuichi Ishikawa, Yukihiko Sugiyama, Hiroyuki Mano	396
20	Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts 2008 ·Clinical Cancer Research ·Kengo Takeuchi, Young Lim Choi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Yuichi Ishikawa, Hiroyuki Mano	397

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact